SS
NTLA icon

SBI Securities’s Intellia Therapeutics NTLA Stock Holding History

SBI Securities’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.4K Sell
2,090
-400
-16% -$5.6K ﹤0.01% 1301
2026
Q1 		$31.9K Sell
2,490
-171
-6% -$2.18K ﹤0.01% 1279
2025
Q4 		$23.9K Sell
2,661
-5
-0.2% -$69 ﹤0.01% 1367
2025
Q3 		$46K Buy
2,666
+626
+31% +$7.71K ﹤0.01% 1121
2025
Q2 		$19.1K Buy
2,040
+336
+20% +$2.76K ﹤0.01% 1425
2025
Q1 		$12.1K Buy
1,704
+32
+2% +$323 ﹤0.01% 1531
2024
Q4 		$19.5K Buy
+1,672
New +$26.1K ﹤0.01% 1362

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

SBI Securities's NTLA Position: Q2 2026 in Review

SBI Securities reduced its Intellia Therapeutics (NTLA) stake by 16% in Q2 2026, selling an estimated $5.6K and leaving 2,090 shares worth $35.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1301.

SBI Securities first reported a position in NTLA in Q4 2024 and has held it in 7 quarters since. The position peaked at $46K in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • SBI Securities held 2,090 shares of Intellia Therapeutics worth $35.4K as of Q2 2026.
  • SBI Securities sold 400 Intellia Therapeutics shares in Q2 2026, an estimated $5.6K.
  • Intellia Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1301 holding.
  • SBI Securities first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Intellia Therapeutics position peaked at $46K in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.